Standout Papers

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre... 2017 2026 2020 2023 878
  1. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017)
    Jacob Schachter, Antoni Ribas et al. The Lancet
  2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (2019)
    Caroline Robert, Antoni Ribas et al. The Lancet Oncology
  3. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019)
    Omid Hamid, Caroline Robert et al. Annals of Oncology

Immediate Impact

4 by Nobel laureates 25 from Science/Nature 81 standout
Sub-graph 1 of 22

Citing Papers

Cutaneous melanoma
2023 Standout
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
7 intermediate papers

Works of Nageatte Ibrahim being referenced

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
2019 Standout
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
2018
and 5 more

Author Peers

Author Last Decade Papers Cites
Nageatte Ibrahim 4616 2253 1799 80 5.6k
Pier Francesco Ferrucci 3616 2889 1631 139 6.1k
Ragini R. Kudchadkar 2527 1538 1247 127 3.8k
April K.S. Salama 2703 1236 1153 129 3.9k
Ester Simeone 3111 1447 1576 113 4.3k
David Hogg 3865 3206 1137 121 6.2k
Jose Lutzky 3383 1822 1861 133 4.7k
Michael Yellin 4616 1602 5133 110 8.1k
Lawrence E. Flaherty 3409 2386 1712 117 5.3k
Marcus O. Butler 4701 1686 3540 245 6.6k
Paola Queirolo 5242 2947 2450 229 7.1k

All Works

Loading papers...

Rankless by CCL
2026